Documente Academic
Documente Profesional
Documente Cultură
Generic Name: Clobetasol Cream, Gel, and Ointment (kloe BAY ta sol)
Brand Name: Embeline, Temovate
Overview
Side Effects
Dosage
Professional
Interactions
Pregnancy
More
This is not a list of all drugs or health problems that interact with clobetasol cream,
gel, and ointment.
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural
products, vitamins) and health problems. You must check to make sure that it is safe
for you to take clobetasol cream, gel, and ointment with all of your drugs and health
problems. Do not start, stop, or change the dose of any drug without checking with
your doctor.
What are some things I need to know or do while
I take Clobetasol Cream, Gel, and Ointment?
Tell all of your health care providers that you take clobetasol cream, gel, and ointment. This
includes your doctors, nurses, pharmacists, and dentists.
Do not use to treat diaper rash.
Do not use clobetasol cream, gel, and ointment to treat acne, rosacea, or a rash around the
mouth.
Use care when putting on a large part of the skin or where there are open wounds. Talk with
the doctor.
Talk with your doctor before you use other drugs or products on your skin.
Do not put on cuts, scrapes, or damaged skin.
Do not use longer than you have been told by the doctor.
This medicine may cause harm if swallowed. If clobetasol cream, gel, and ointment is
swallowed, call a doctor or poison control center right away.
This medicine may raise the chance of cataracts or glaucoma. Talk with the doctor.
Use with care in children. Talk with the doctor.
This medicine may affect growth in children and teens in some cases. They may need regular
growth checks. Talk with the doctor.
Some products are not approved for use in children. Talk with the doctor.
Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about
the benefits and risks of using clobetasol cream, gel, and ointment while you are pregnant.
Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.
If you are breast-feeding, do not put clobetasol cream, gel, and ointment right on the nipple
or the area right around it.
Use as you have been told, even if your signs get better.
Do not take clobetasol cream, gel, and ointment by mouth. Use on your skin only. Keep out
of your mouth, nose, and eyes (may burn).
Wash your hands before and after use. Do not wash your hands after use if putting this on
your hand.
Clean affected part before use. Make sure to dry well.
Put a thin layer on the affected skin and rub in gently.
Do not put on the face, underarms, or the groin area unless told to do so by the doctor.
Do not use coverings (bandages, dressings, make-up) unless told to do so by the doctor.
See also:
Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin
with or without fever; wheezing; tightness in the chest or throat; trouble breathing,
swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or
throat.
Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing
urine more often, flushing, fast breathing, or breath that smells like fruit.
Signs of Cushing's disease like weight gain in the upper back or belly, moon face, very bad
headache, or slow healing.
Signs of a weak adrenal gland like a very bad upset stomach or throwing up, very bad
dizziness or passing out, muscle weakness, feeling very tired, mood changes, not hungry, or
weight loss.
Skin changes (pimples, stretch marks, slow healing, hair growth).
Irritation where clobetasol cream, gel, and ointment is used.
Thinning of the skin.
Change in eyesight, eye pain, or very bad eye irritation.
Stinging.
Dry skin.
Burning.
Redness.
These are not all of the side effects that may occur. If you have questions about side
effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088. You may also report
side effects at http://www.fda.gov/medwatch.
See also:
If OVERDOSE is suspected:
If you think there has been an overdose, call your poison control center or get medical
care right away. Be ready to tell or show what was taken, how much, and when it
happened.
Further information
Always consult your healthcare provider to ensure the information displayed on this
page applies to your personal circumstances.
Clobetasol topical Side Effects
Medically reviewed on Jun 7, 2018
Overview
Side Effects
Dosage
Professional
Interactions
Pregnancy
More
Along with its needed effects, clobetasol topical may cause some unwanted effects.
Although not all of these side effects may occur, if they do occur they may need
medical attention.
Check with your doctor immediately if any of the following side effects occur while
taking clobetasol topical:
More Common
Less Common
Rare
Thinning, weakness, or wasting away of the skin
Burning, itching, and pain in hairy areas, or pus at the root of the hair
hair loss
hives
redness and scaling around the mouth
thinning of the hair
Some side effects of clobetasol topical may occur that usually do not need medical
attention. These side effects may go away during treatment as your body adjusts to the
medicine. Also, your health care professional may be able to tell you about ways to
prevent or reduce some of these side effects. Check with your health care professional
if any of the following side effects continue or are bothersome or if you have any
questions about them:
More Common
Cough
sore throat
Less Common
Acne or pimples
burning and itching of the skin with pinhead-sized red blisters
increased hair growth on the forehead, back, arms, and legs
lightening of normal skin color
lightening of treated areas of dark skin
reddish purple lines on the arms, face, legs, trunk, or groin
softening of the skin
For Healthcare Professionals
Applies to clobetasol topical: compounding powder, topical cream, topical foam,
topical gel, topical kit, topical lotion, topical ointment, topical shampoo, topical
solution, topical spray
General
Endocrine
Dermatologic
Local
Ocular
Other
Gastrointestinal
Postmarketing reports: Nausea[Ref]
Metabolic
Nervous system
References
Further information
Always consult your healthcare provider to ensure the information displayed on this
page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
Medical Disclaimer
Overview
Side Effects
Dosage
Professional
Interactions
Pregnancy
More
Dermatitis
Eczema
Psoriasis
Dermatological Disorders
Lichen Planus
Dermatitis
Eczema
Psoriasis
Dermatological Disorders
Lichen Planus
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce)
per week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Relief of corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Usual Adult Dose for Eczema
-Solution, spray, ointment, gel, foam, lotion, cream formulations: Apply a thin layer
to affected areas twice a day and rub in gently and completely.
-Shampoo: Apply to dry scalp once a day in a thin film to the affected areas only and
leave in place for 15 minutes before lathering and rinsing.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce)
per week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Relief of corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce)
per week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Relief of corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce)
per week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Relief of corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fluid ounce)
per week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Relief of corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per
week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per
week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per
week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Maximum dose: The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per
week.
Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief
of the inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses and up to 2 additional weeks in localized lesions (less than 10% body
surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.
Comments: Unless directed by a healthcare professional, this drug should not be used
with occlusive dressings.
Uses:
-Corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis;
recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions
which do not respond satisfactorily to less active steroids.
Precautions
-If treatment is required for use in children, it is recommended that it should be
reviewed weekly.
Safety and efficacy have not been established in patients younger than 18 years and its
use in pediatric patients under 12 years of age is not recommended.
Dialysis
Data not available
Other Comments
Administration advice:
-Do not use on your face, groin, armpits, lips, or in your eyes.
-Do not cover your head with a shower cap or bathing cap.
-Wash your hands after applying the drug unless it is the hands that are being treated.
-If drug enters the eye, the affected eye should be rinsed immediately with plenty of
water.
Further information
Always consult your healthcare provider to ensure the information displayed on this
page applies to your personal circumstances.
Medical Disclaimer